SCHEMBL2340937

SCHEMBL2340937

CNC(=O)c1ccc2c(c1)ncn2-c1cccc(-c2cccc(NC(C)=O)c2)c1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
FGFR1 P11362 6/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
RIPK1 Q13546 1/20 0.51
RIPK3 Q9Y572 1/20 0.51
HPGD P15428 3/20 0.49
TP53 P04637 2/20 0.48
MAPT P10636 1/20 0.48
FYN P06241 1/20 0.48
ATM Q13315 1/20 0.47
ADRA2B P18089 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2337170 0.87 FGFR1 (0.60) NPC1RAB9AFGFR1SMN1; SMN2RIPK1
SCHEMBL2339832 0.86 ATM (0.49) FGFR1SMN1; SMN2RIPK1RIPK3HPGD
SCHEMBL2340939 0.84 MAPK1 (0.60) NPC1RAB9AFGFR1SMN1; SMN2RIPK1
SCHEMBL2337601 0.84 HPGD (0.57) NPC1RAB9AFGFR1SMN1; SMN2RIPK1
SCHEMBL4503339 0.83 NPC1 (0.70) NPC1RAB9AFGFR1SMN1; SMN2HPGD
SCHEMBL2337759 0.82 GABRA1 (0.63) NPC1RAB9AFGFR1SMN1; SMN2RIPK1
SCHEMBL2335978 0.82 FGFR1 (0.52) NPC1RAB9AFGFR1SMN1; SMN2RIPK1
SCHEMBL2337743 0.82 HPGD (0.49) NPC1RAB9AFGFR1SMN1; SMN2RIPK1
SCHEMBL2641968 0.82 NPC1 (0.62) NPC1RAB9AFGFR1SMN1; SMN2HPGD
SCHEMBL2338457 0.81 HPGD (0.48) NPC1RAB9AFGFR1SMN1; SMN2RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831206-B1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARM INC (US) 2011-08-24 EP claimed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US claimed
JP-2008521903-A 2008-06-26 JP claimed
EP-1831206-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI Pharmaceuticals, Inc. (US) 2007-09-12 EP claimed
WO-2006060381-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARMACEUTICALS, INC. (US) 2006-06-08 WO claimed
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. 2006-06-01 US claimed
EP-1831206-B1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARM INC (US) 2011-08-24 EP disclosed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library KIT, CHUK, TNNI3K NPC1 1346/4885RAB9A 1598/4885FGFR1 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.